SCHEMBL23888703

SCHEMBL23888703

CCn1cc(-c2cc(Oc3ccc(N)nc3)ccn2)cn1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 9/20 0.51
▸ CSF1R P07333 9/20 0.45
▸ PDGFRA P16234 4/20 0.45
▸ FLT3 P36888 2/20 0.45
▸ PDGFRB P09619 4/20 0.41
▸ MET P08581 2/20 0.41
▸ KDR P35968 2/20 0.41
▸ KIT P10721 4/20 0.41
▸ BTK Q06187 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30086972 1.00 PIM1 (0.51) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL23900467 0.86 TGFBR1 (0.47) CSF1RPDGFRAFLT3PDGFRBMET
SCHEMBL30086949 0.84 CSF1R (0.54) CSF1RPDGFRAFLT3PDGFRBMET
SCHEMBL2416158 0.84 CSF1R (0.54) CSF1RPDGFRAFLT3PDGFRBMET
SCHEMBL3039678 0.84 PIM1 (0.49) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL16028718 0.82 CSF1R (0.59) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL23888677 0.82 CSF1R (0.39) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL30086888 0.82 CSF1R (0.39) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL23900709 0.81 PIM1 (0.47) PIM1CSF1RPDGFRAFLT3PDGFRB
SCHEMBL30086828 0.81 PIM1 (0.47) PIM1CSF1RPDGFRAFLT3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 — — US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 — — US disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-29 — — CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 — — CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 — — CN disclosed
CN-115315422-B Amide compound and application thereof 和记黄埔医药(上海)有限公司 2023-11-07 — — CN disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 — — US disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 — — EP disclosed
CN-115315422-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2022-11-08 — — CN disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 — — WO disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, ASS1, NAT1 PIM1 1815/4885CSF1R 2941/4885PDGFRA 3533/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 PIM1 1815/4885CSF1R 2941/4885PDGFRA 3533/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC PIM1 1860/4885CSF1R 3035/4885PDGFRA 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback